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RATIONALE AND BACKGROUND INFORMATION {#s2}
====================================

Epidemiology of Subarachnoid Hemorrhage {#s2-1}
---------------------------------------

Stroke is a leading cause of morbidity and mortality worldwide. Subarachnoid hemorrhage (SAH), which accounts for approximately 5% of all types of stroke,[@R1] generally results from the spontaneous hemorrhage of a brain aneurysm. The annual incidence of SAH is 10/100 000 worldwide. In patients with poor-grade SAH, in-hospital mortality rates range from 34% (Hunt and Hess grade IV, stupor) to 52% (Hunt and Hess grade V, coma); however, 3 decades ago, these rates were approximately twice as high.[@R2]

Pathophysiology of SAH {#s2-2}
----------------------

### Cerebral Blood Flow and Metabolism {#s1-2-1}

Cerebral hemodynamics are linked to brain metabolism. Regional blood flow is proportional to the demand for oxygen and glucose, which is the principal energy substrate for neurons. Histologically, the link between cerebral hemodynamics and brain metabolism is explained by the neurovascular unit,[@R3] which constitutes the blood-brain barrier (BBB). The vascular components of the neurovascular unit are the endothelial cells, contractile cells that surround the endothelial cells (myocytes in the arterioles and pericytes in the capillaries), and the basal lamina of the vessel. The neural components of the neurovascular unit are the astrocytes, which project throughout the vessels, and the neurons, which are more peripherally located and are in contact with the astrocytes. Between the vascular and neural components lies the Virchow-Robin space, which is an inflection of the leptomeninges over the pial vessels at the point where these vessels enter the brain parenchyma. Therefore, in theory, lesions of the neurovascular unit can release molecules and cells that are detectable by laboratory tests into both the cerebrospinal fluid (CSF) and the bloodstream.

Overall, cerebral blood flow (CBF) remains relatively stable at between 80% and 120% of baseline,[@R4] despite variations in the cerebral perfusion pressure (CPP). This mechanism is known as cerebral autoregulation or, more specifically, static cerebral autoregulation, and was first described by Lassen in 1959.[@R5] The CPP is calculated by subtracting the intracranial pressure (ICP) from the mean arterial pressure. Static cerebral autoregulation is maintained when CPP values are within the approximate range of 50 to 150 mm Hg. Outside of this range, the CBF varies as a function of the CPP. Nevertheless, in recent years, a phenomenon known as dynamic cerebral autoregulation, in which rapid and subtle changes in the CBF occur, has been described.[@R4] Such short-term CBF variations occur within a CPP range where the long-term CBF remains stable; in other words, dynamic and static cerebral auto-regulation mechanisms are simultaneous.

Clinically, dynamic cerebral autoregulation can be evaluated by transcranial Doppler (TCD), using parameters such as the pulsatility index and the CO~2~ reactivity, which are based on the principle of an inverse relationship between blood vessel flow and resistance. The pulsatility index is given by the difference between the systolic and diastolic velocities in a given artery (generally the middle cerebral artery \[MCA\]), divided by the mean velocity. In addition, CO~2~ reactivity can evaluate the cerebrovascular reserve capacity; when CO~2~ reactivity is preserved, variations in arterial CO~2~ tension elicit a proportional blood velocity response in blood vessels such as the MCA.

Under pathological conditions, such as SAH, the oxygen supply may not be sufficient to meet the energetic demand in certain regions of the brain. Prolonged hypoxia leads to a gradual change in neurons, as originally described by Opitz and Schneider in 1950.[@R6] At a flow of approximately 55 mL/100 g per min, neurons are functionally inactive but remain viable, forming the ischemic penumbra. Below 35 mL/100 g per min, anaerobic glycolysis predominates. Below 15 mL/100 g per min, the cell membrane is damaged, which leads to cell death. Nevertheless, adequate blood flow and an adequate supply of glucose and oxygen do not necessarily translate into adequate energy production, as demonstrated in recent studies. This phenomenon, known as the metabolic penumbra,[@R7] has been attributed to mitochondrial dysfunction.

In summary, an imbalance between the energy substrate\'s supply and demand appears to be the principal trigger for brain cell injury. When this imbalance occurs, protective mechanisms are activated. However, the persistence of such an imbalance leads to the progression of cell injury mechanisms, including the cytotoxic effects of glutamate, massive calcium influx into the cell, free radical formation, proinflammatory cytokine production, apoptosis, and necrosis.[@R6] Although such factors are interrelated, they are only pieces of a puzzle that is far from complete. In broad terms, such factors are common to the pathophysiology of all types of severe acute brain injury, including SAH.

Phases of SAH {#s2-3}
-------------

Classically, in addition to hydrocephalus and rebleeding, the principal neurological complication of SAH is vasospasm.[@R8] However, 2 changes that precede the onset of vasospasm, ie, early brain injury and cortical spreading depression (depolarization), have recently been described as relevant factors for SAH-related morbidity.

Early brain injury refers to pathophysiological mechanisms that occur within the first 72 hours after a stroke.[@R1] In patients with SAH, aneurysmal bleeding initially leads to ischemia, BBB damage, and cytotoxic edema. A cascade of molecular and cellular events may occur in this phase. Among such events, apoptosis, triggered principally by the activation of the cytochrome *c* and caspase pathways, plays a significant role.

Spreading depression (SD) was first described in 1944 by the Brazilian physiologist Leão.[@R9] In models of ischemia, SD is a mechanism of injury in which waves of depolarization are generated from a central region of necrosis to the periphery of the ischemic penumbra. The pathophysiological substrate of SD is exacerbated glutamate release. In a study of SAH patients, SD was detected by using chronic electrocorticography in the period following aneurysm clipping.[@R9] In this study, a strong correlation between the frequency of SD and the incidence of delayed ischemic neurological deficits was observed.

Vasospasm may occur from 3 to 5 days after SAH; its incidence is higher between posthemorrhage days 5 and 14, progressively lower in the following 2 weeks, and practically absent in later periods.[@R10] Vasospasm has been attributed to hemoglobin degradation products.[@R8] The iron, heme, and biliverdin that are released during degradation contribute to the formation of free radicals. More recently, other mechanisms for vasospasm have been described, with endothelin appearing to play a role in increasing cerebral vascular tone; in addition, inflammatory and apoptotic activities mediate cell proliferation and the increased number of myocytes in the arteriole walls.

SAH also causes systemic changes. Clinically, there is an association between SAH and the systemic inflammatory response syndrome.[@R11] Moreover, SAH patients develop myocardial dysfunction, which manifests as electrocardiographic changes and altered cardiac output.[@R2] Right atrial distension may increase the production of brain natriuretic peptide, which is produced almost exclusively by the heart in humans. The high incidence of cerebral salt-wasting syndrome in SAH is partially explained by the interrelationship of these phenomena.[@R12]

Inflammation {#s2-4}
------------

During the first week after acute cerebral ischemia, the central nervous system is affected by a proinflammatory phase.[@R13] Inflammatory activity is increased by various factors, namely: (1) production of reactive oxygen species; (2) production of cytokines and chemokines by neurons and astrocytes; (3) activation of the endogenous macrophages of brain parenchyma (microglia); (4) rupture of the BBB; and (5) endothelial cell expression of selectins, especially intercellular adhesion molecule-1.[@R14] The proinflammatory phase is characterized by the participation of enzymes (matrix metalloproteinases 2 and 9), cytokines (tumor necrosis factor alpha, interferon gamma, interleukin \[IL\]-1β, IL-2, and IL-6), chemokines (monocyte chemoattractant protein-1 and stromal cell-derived factor-1 alpha), and cells (microglia and certain lymphocytes).

The proinflammatory phase is followed by an anti-inflammatory phase, which is similar to sepsis.[@R15] In cerebral ischemic injury, the activity of IL-10 and regulatory T lymphocytes predominates. In fact, higher levels of IL-10 and greater numbers of regulatory T lymphocytes in the ischemic brain lead to a lower stroke volume.[@R16] However, from a systemic standpoint, the anti-inflammatory phase contributes to the onset of infection.

Contradictory effects of certain cytokines have been reported. IL-6 has been reported to both improve and worsen cerebral ischemic injury.[@R14] The effects of tumor necrosis factor alpha seem to depend on the type of receptor that is activated.[@R17] Microglia and chemokines have different effects that appear to be phase dependent. In the proinflammatory phase, microglia and chemokines attract leukocytes and prevent newly formed neurons (neuroblasts) from surviving. However, in the anti-inflammatory phase, they contribute to the survival, migration, maturation, and integration of migrating neuroblasts.[@R14],[@R17]

Neuroregeneration {#s2-5}
-----------------

Adult neurogenesis in humans has been recently described.[@R18] Adult mammalian neurogenesis occurs physiologically in the subventricular zone (SVZ) and in the subgranular zone (SGZ) of the dentate gyrus in the hippocampus, but it may also occur in pathological situations. Thus, neurogenesis is increased in models of cerebral ischemia.[@R19] In humans, ischemic stroke triggers the emergence of cells around the site of the injury.[@R20] These cells are positive for neurogenesis-related markers, such as βIII-tubulin, but the true significance of this finding is controversial because βIII-tubulin is also present in normal human brains.[@R21] Specifically, in SAH, brain samples from SAH patients have been reported to contain an increased number of neural stem cells.[@R22]

The pathophysiological mechanisms that are present in SAH can trigger an increase in neurogenesis. SD has been reported to trigger increased neurogenesis in the SVZ[@R23] and in the SGZ of the dentate gyrus.[@R24] In addition, the subpial zone, which is supposedly nonneurogenic under physiological conditions, has been reported to show the same type of response to SD.[@R25] One controversy in this line of research has regarded the location of neurogenic niches in normal and diseased human brains.[@R21]

To clarify this issue, as shown in Figure [1](#F1){ref-type="fig"}, our group mapped neurogenic niches in humans. We have confirmed the existence of neurogenesis markers in the SVZ and SGZ.[@R26] Likewise, nestin, a neural stem cell marker, has been detected in the isocortex (which is supposedly a nonneurogenic area under physiological conditions) of a sample obtained from a patient with epilepsy (data not shown). Analogously, epileptic seizures in patients with SAH may trigger the same type of response.

![Anatomic structures and cell phenotypes potentially involved in constitutive and injury-induced neurogenesis. This figure displays figures from histologically normal brains analyzed in our previous study,[@R26] which showed the existence of a potential neurogenic system between the hypothalamus and the hippocampus. **A** and **B** are brain specimens showing the choroid plexus (1) and the fimbria (2), which are structures in the hypothalamus-hippocampus axis that express neurogenesis markers.[@R26] The BBB is normally absent in the choroid plexus and in the neurovascular unit during brain injury, which may indicate a role of the neurovascular unit in injury-induced neurogenesis. Interestingly, the structures of the neurovascular unit (**C**-**G**) express the neural stem cell marker nestin, although the implications of this expression are unclear. **C**-**F** are images of confocal microscope showing colabeling between nestin (green) and the marker of BBB glucose transporter-1 (glut-1) (red) in brain endothelial cells. **G** is an image of chromogenic immunofluorescence showing nestin expression in the endothelium and in a neurovascular unit astrocyte, both stained in brown with DAB. **3**, dentate gyrus and margo denticulatus; **4**, uncus; **5**, parahippocampal gyrus; **6**, optic tract; **7**, tail of the hippocampus; bv, blood vessel. Arrows: In **A**, taenia fornicis (boundary between the choroid plexus and the fimbria); in **F**, colabeling of nestin and glut-1 in endothelial cell; and in **G**, nestin expression in neurovascular unit astrocyte (the arrowhead in **G** points to an end foot of this astrocyte). Arrowhead in **A**: Inferior choroidal point (anterior limit of the fimbria and the choroid plexus in the temporal lobe). Asterisk: Zone of the piriform cortex. Blue color indicates cell nuclei stained with DA I. Scale bars: **C**-**F** = 10 µm, **G** = 20 µm. BBB, blood-brain barrier; DAB, 3,3′-diaminobenzidine; DAPI, 4\',6-diamidino-2-phenylindole.](neu-75-678-g001){#F1}

The correlation between individual variations in the injury-induced neurogenesis and functional outcome is unknown. Our study suggests that this correlation may be significant, because we have shown that the human brain expresses neurogenesis markers in a continuous area between the hippocampus and hypothalamus.[@R26] This area is larger than previously thought and involves the circumventricular organs, where the BBB is absent. The mechanisms underlying possible neurogenesis arising in the circumventricular organs may be enhanced during injury-induced neurogenesis by the breakdown of the BBB.

Under pathological conditions, the relationship between hematopoiesis, neurogenesis, and vasculogenesis occurs at different levels. Thus, sublethal ischemia induces collateral vessel formation in the pial vessels (ischemic preconditioning).[@R6] Granulocyte colony-stimulating factor, a growth factor with a previously studied neurogenic potential, is involved in this process.[@R27] Additionally, erythropoietin (which was discovered in studies of hematopoiesis) was tested in a phase II clinical trial of patients with SAH who had improved outcomes.[@R28] It has been suggested that erythropoietin may improve outcomes through a neuroprotective effect. In contrast, vascular endothelial growth factor, which stimulates vasculogenesis, seems to contribute to worse SAH outcomes.[@R29]

In summary, SAH triggers an intense inflammatory response, initiating a proinflammatory phase that is followed by an anti-inflammatory phase. In each phase, various cells, cytokines, and chemokines predominate. Some of these cells and molecules are present in both phases, and their effects depend on the context. Initially, they are proinflammatory. Subsequently, they are thought to participate in mechanisms of neuroregeneration, although this has yet to be confirmed, especially in humans.

Multimodality Monitoring {#s2-6}
------------------------

### Current State of Multimodality Monitoring in Neurocritical Care {#s2-6-1}

The most important aspect of the management of poor-grade SAH is clinical evaluation. However, clinical evaluation is not sufficient for understanding the true condition of the central nervous system or anticipating declines in function. Therefore, monitoring of physiological parameters is required. In practice, because of the risks and benefits of the individual methods, a combination of methods is used. Obtaining data in this manner is known as multimodality monitoring. In the literature, multimodality monitoring is considered one of the principal strategies for defining both the treatment and outcome in some severe neurological diseases.

### Multimodality Monitoring Methods {#s2-6-2}

#### Transcranial Doppler {#s1-6-2-1}

TCD is an ultrasound-based method for evaluating cerebral hemodynamics.[@R30] As previously mentioned, TCD provides data on the CBF, cerebral autoregulation, and cerebral hemodynamic reserve. In SAH cases, TCD is widely used to detect vasospasm, based on parameters such as the Lindegaard ratio (the ratio between the MCA flow velocity and the internal carotid artery flow velocity). TCD is particularly recommended for the diagnosis of severe vasospasm.[@R10]

#### Continuous Electroencephalography {#s2-6-2-2}

Continuous electroencephalography (EEG) is a noninvasive method. In poor-grade SAH, this method is principally indicated for detecting epileptic seizures, predicting the onset of delayed cerebral ischemia, and monitoring sedation. Epileptic seizures are common and worsen outcomes, regardless of the frequent absence of clinical repercussions. Claassen et al[@R31] conducted a study of 108 patients with SAH and diagnosed clinical epileptic seizures in 19% of these patients. Of the entire sample, 18% had nonconvulsive seizures and 13% had nonconvulsive status epilepticus. Periodic epileptiform discharges, principally periodic lateralized epileptiform discharges, occurred in 23% of the patients. Such discharges are supposed to correspond to a spectrum between interictal and ictal activity.

Continuous EEG can predict delayed cerebral ischemia as early as 2 days before its onset.[@R32] The principal change, observed in over 50% of the patients, is a decrease in the alpha/delta ratio. The methods for quantifying such patternwould alert the intensivist, precluding the need for interpretation by an EEG specialist, which is a disadvantage of EEG. Similarly, EEG data may be quantified by the bispectral index, which is used to determine the level of sedation, although its prolonged use in the intensive care unit setting has yet to be validated. Another parameter for the evaluation of sedation is the presence of burst suppression. EEG data acquisition may be hampered by local factors, such as scalp edema and space limitations due to the presence of catheters and surgical incisions.

#### Monitoring of ICP, Brain Temperature, and Brain Tissue Oxygenation (P~ti~[o]{.smallcaps}~2~) {#s2-7}

The ICP, brain temperature, and P~ti~[o]{.smallcaps}~2~ are monitored by intracranial catheters. The most widely used of these 3 methods is ICP monitoring.[@R33] ICP values \>20 mm Hg are associated with a poor outcome. An intraventricular catheter is considered to be the most accurate type of ICP-monitoring catheters and has the advantage of allowing CSF drainage to manage intracranial hypertension. A disadvantage of the ventricular catheter is an increased likelihood of infection, especially after 5 to 7 days of use.

Brain temperature monitoring is warranted because of its association with outcomes in poor-grade SAH.[@R34] Brain temperature monitoring is a less established and more invasive method of predicting outcome compared with body temperature monitoring. Nevertheless, the exact relationship between the brain and body temperature measurements in severe neurological conditions is unknown, and their values may not match. Thus, in poor-grade SAH cases where ICP monitoring is performed, brain temperature monitoring does not pose additional or unnecessary risks, provided that the same catheter is used to monitor both the ICP and the brain temperature. Finally, P~ti~[o]{.smallcaps}~2~ can add to multimodality monitoring by displaying tissue hypoxia, eg, when its value in the white matter is below 20 mm Hg.[@R33] A limitation of monitoring the brain temperature and P~ti~[o]{.smallcaps}~2~ is the lack of validated parameters. Moreover, the P~ti~[o]{.smallcaps}~2~ catheter cannot detect hypoxia that occurs in areas distant from its position in the brain parenchyma, which is another limitation because brain tissue oxygenation may be heterogeneous in SAH.

#### Brain Microdialysis {#s2-7-1}

Microdialysis was introduced to neuroscience in the 1970s. It was first used clinically in the 1990s.[@R35] Microdialysis is performed by placing a 1-mm probe into the area of interest. In patients with SAH, the probe can be inserted during craniotomy. Another option is to use a screw to attach the microdialysis probe to the remaining catheters for multimodality monitoring (P~ti~[o]{.smallcaps}~2~, brain temperature, and parenchymal ICP). The consensus is that the probe must be placed in the area that is fed by the artery with the aneurysm. The risks of infection and bleeding are low. Some authors have reported that microdialysis probes can be maintained for up to approximately 10 days.

Microdialysis probes allow for the collection of potentially cytotoxic neurotransmitters (glutamate), energy substrates (glucose), and glucose metabolites (lactate and pyruvate), as well as molecular markers of membrane damage (glycerol). Monitoring glucose, lactate, and pyruvate levels allows for the evaluation of glycolysis. In the absence of oxygen or when the mitochondrial oxygen uptake is inadequate, pyruvate is converted into lactate, a process that is far less energy efficient. In practice, the principal parameter evaluated in the diagnosis of metabolic stress is the lactate/pyruvate ratio, and values higher than 40 are classified as altered. In a study of patients with SAH, the metabolic parameters studied through microdialysis allowed the authors to predict vasospasm an average of 7.8 hours before its onset.[@R35] Despite its potential, brain microdialysis requires further validation. Moreover, another limitation of this method is that it provides data on only a single area of the brain parenchyma.

Aspects of the Treatment of Poor-Grade SAH {#s2-8}
------------------------------------------

### Evidence-Based Medicine {#s2-8-1}

The American Stroke Association has recently systematized the guidelines for SAH.[@R10] The Brain Trauma Foundation has outlined practices for monitoring ICP and cerebral hemodynamics, although such practices are not directly related to poor-grade SAH.[@R36] For more controversial issues, such as multimodality monitoring, guidelines based on currently available evidence can be found.[@R37] However, high-level evidence and grades of recommendation remain rare in SAH, trauma, and multimodality monitoring guidelines. This partially explains why a recent study on numerous centers worldwide found discrepancies in the approaches to the most important aspects of SAH.[@R38]

### Neuroprotection {#s2-8-2}

The approach to treating poor-grade SAH involves measures that are aimed at avoiding the progression of secondary ischemic injury. Such measures include sedation, hyperosmolar therapy, and monitoring clinical parameters. Moreover, the neuroprotectiverole of hypothermia has become clear.[@R39] Hypothermia has been reported to act on virtually all secondary injury mechanisms, including the modulation of the inflammatory response. The principal adverse effects of hypothermia include cardiac arrhythmia, coagulopathies, and a higher risk of infection. In addition, effective temperature control can be complex in clinical practice.[@R40],[@R41] We speculate that some disadvantages of hypothermia may be overcome by the development of a straightforward method for cooling neural tissue (eg, CSF cooling), which avoids the technical obstacle of the low thermal conductivity of the skull.

Translational Medicine: Surrogate Biomarkers {#s2-9}
--------------------------------------------

Correlations between functional outcomes and data obtained from both multimodality and laboratory monitoring may help to overcome a major obstacle in the development of new stroke therapies, namely, the need for a large number of patients to confirm the effect of any given therapeutic approach. Thus, the number of patients required to confirm whether a given treatment improves clinical vasospasm is estimated to be more than 5000.[@R42] Although controversial, an alternative approach is the use of a surrogate biomarker.[@R43] The physiological, cellular, and molecular analyses proposed in the protocol below constitute potential biomarkers for SAH management.

STUDY GOALS AND OBJECTIVES {#s3}
==========================

This project has 1 clinical and 1 experimental goal. The clinical goal is to assess the safety and potential improvement in poor-grade SAH outcomes via a protocol of multimodal monitoring-guided therapeutic hypothermia. The experimental goal is to clarify the mechanisms of inflammation and neuroregeneration involved in poor-grade SAH, emphasizing the potential development of novel therapies for acute and severe neurological injuries.

The specific objectives of this study are:Evaluate the complications and technical difficulties of the proposed protocol;Compare clinical monitoring methods in terms of their predictive value for vasospasm and relevance for management;Analyze the effects of rigorous control of brain temperature, P~ti~[o]{.smallcaps}~2,~ and metabolic stress on the clinical outcomes and inflammatory response;Correlate pro- and anti-inflammatory markers with neurogenesis-related markers in blood and cerebrospinal fluid; andCorrelate inflammation and neurogenesis-related markers with delayed brain ischemia, multimodality monitoring data, and clinical outcomes.

STUDY DESIGN {#s4}
============

Protocol Proposal {#s4-1}
-----------------

### General Aspects {#s4-1-1}

The number of studies investigating each of the items addressed in this study is considerable. However, few studies have attempted to simultaneously investigate these items. Our objective was to do so and to reach conclusions that may have potential practical applications. Therefore, we deemed it more appropriate to present the proposal of a protocol for the multimodality monitoring of patients with poor-grade SAH and a concomitant analysis of the molecular and cellular markers related to inflammation and neuroregeneration. As with any other protocol, the decision to implement the particular protocol proposed here should be made on a case-by-case basis, taking into account multiple and unpredictable clinical variables. In addition, the present protocol is intended as a starting point and is open to criticism and adaptations. Our protocol may be adapted to other acute, diffuse, and severe neurological diseases. Nevertheless, certain relevant guidelines should be followed, namely the following: (1) it should be implemented only at centers with extensive experience in SAH[@R38]; (2) a multidisciplinary team should be available; (3) it should be approved by the local research ethics committee; and (4) suitable financial support should be sought.

### Type of Clinical Trial and Inclusion and Exclusion Criteria {#s3-1-2}

Due to the clinical characteristics of the patients, the present protocol is suitable for a prospective, observational study that has an end point by October 2016. The expected sample size is 20 patients. The inclusion criteria are as follows: (1) patients who are 18 to 65 years of age; (2) hospitalization within the first 72 hours after the first hemorrhage; (3) presentation with Hunt and Hess grade IV or V; and (4) presentation with an anterior circulation aneurysm. The exclusion criteria are: (1) a neurosurgical procedure at another facility due to SAH (eg, placement of an external ventricular drain); (2) presentation with a severe systemic disease; and (3) presentation with either a Glasgow coma scale score of 3 or pathological posturing accompanied by bilateral mydriasis with fixed pupils.

METHODOLOGY {#s5}
===========

Clinical Data {#s5-1}
-------------

We will collect data on the clinical evolution (Table [1](#T1){ref-type="table"}), laboratory tests (eg, those specified in Table [1](#T1){ref-type="table"}), prescriptions, and interventions guided by multimodality monitoring. Continuous measurements will be stored by commercially available monitoring systems that simultaneously display vital signs, mechanical ventilation data, and the majority of neurological multimodality monitoring parameters. Likewise, an EEG device will separately be used to continuously store data. TCD and a cranial CT scan will be performed at least daily and every 3 days, respectively.

###### 

Intensive Care Unit Notes^a^

![](neu-75-678-g002)

The treatment of poor-grade SAH, guided by multimodality monitoring, is presented as follows: admission, aneurysm occlusion, and catheter placement (Table [2](#T2){ref-type="table"}); parameter definition and management regarding multimodality monitoring methods (Table [3](#T3){ref-type="table"}); and algorithms for clinical vasospasm prophylaxis (Figure [2](#F2){ref-type="fig"}), neuroprotection (Figure [3](#F3){ref-type="fig"}), and removal of multimodality monitoring catheters (Figure [4](#F4){ref-type="fig"}).

###### 

Admission, Aneurysm Occlusion, and Catheter Placement^a^

![](neu-75-678-g003)

###### 

Practices Guided by Multimodality Monitoring^a,b^

![](neu-75-678-g004)

![Algorithm for clinical vasospasm prophylaxis. The most common practice for clinical vasospasm prophylaxis is the 3Hs therapy, ie, hypertension, hypervolemia, and hemodilution. We propose some modifications in the 3Hs therapy, owing to findings regarding clinical vasospasm prophylaxis and cardiovascular management, principally in the past decade. Among the 3 Hs, hypertension has been shown to be the most effective, regardless of the necessity to balance the risk of intracranial hypertension in cases of poor-grade SAH that evolve with lack of cerebrovascular autoregulation. Evaluation of fluid responsiveness is the first option to decide whether to administer fluid or vasoactive drug for blood pressure increase; in the absence of signs of lung congestion, hypervolemia may be considered before neuroprotection measures, which imply a higher risk of adverse effects. The unlikely use of hypervolemia may prevent anemia, the correction of which, through red blood cell transfusion, is based on multimodality monitoring. A/C, assist/control; CI, cardiac index; CVP, central venous pressure; CVSP, clinical vasospasm prophylaxis; Hb, hemoglobin; MAP, mean arterial pressure; MMPs, multimodality monitoring parameters; MV, mechanical ventilation; SBP, systolic blood pressure; SS, saline solution; T, temperature; VAD, vasoactive drug; Vt, tidal volume; ΔSV, systolic volume variation. \* For alternatives to evaluate fluid responsiveness, see [@R44]; if a passive leg-raising test is performed, discontinue this test in case the intracranial pressure becomes higher than 20 mm Hg.](neu-75-678-g005){#F2}

![Algorithm for neuroprotection. Multimodality monitoring parameters guide a progressive use of sedation, hyperosmolar therapy, and hypothermia. We hypothesized that future therapies will be underpinned mainly by the development of research on hypothermia as a method for neuroprotection. BBT, body and brain temperature; BIS, bispectral index; BP, blood pressure; BS, burst suppression; Hb, hemoglobin; MMPs, multimodality monitoring parameters; PB, pentobarbital; RSS, Ramsay Sedation Scale; VAD, vasoactive drug.](neu-75-678-g006){#F3}

![Algorithm for the removal of multimodality monitoring catheters. CSF, cerebrospinal fluid; ICP, intracranial pressure; P~ti~[o]{.smallcaps}~2~, brain tissue oxygenation.](neu-75-678-g007){#F4}

Inflammation and Neuroregeneration Markers {#s5-2}
------------------------------------------

As seen in Table [4](#T4){ref-type="table"}, the inflammation and neuroregeneration markers are of a molecular and cellular nature. The molecular markers will be determined by immunoenzymatic assays, whereas the cellular markers will be detected by flow cytometry. A total of 4 mL of CSF will be collected on the day that the ventricular catheter is inserted and on the day that it is removed, as well as once in between these 2 days. On the same days, 4 mL of blood will be collected. Another 4 mL of blood will be collected on post-SAH days 14, 21, 28, 90, and 180. The material (CSF or blood, 1.5 mL per sample) will be stored at −80°C for immunoenzymatic assays. After collecting samples from groups of 3 patients, immunoenzymatic assays will be performed for all molecules. The remaining samples will be stored at 4°C for weekly flow cytometry. Controls for the cells studied in the blood will be performed by using samples from volunteers. For molecules present in the CSF, 15 samples from patients with an indication for lumbar puncture (eg, screening for SAH, meningitis, or polyradiculoneuritis), whose test results are normal, will be evaluated; this figure has been estimated on the basis of blood sample controls, as described in the directions for use of commercially available reagents.

###### 

Inflammation and Neuroregeneration Markers^a^

![](neu-75-678-g008)

DISCUSSION {#s6}
==========

Various conditions treated in the scope of neurocritical care have high morbidity and mortality rates. One of the greatest challenges is poor-grade SAH. The challenge lies in the development of methods for monitoring and treating SAH as well as in our understanding of the pathophysiology of SAH. Therefore, SAH is a potential model for the standardization of multimodality monitoring as well as for studies of the influence of inflammation and neuroregeneration mechanisms in stroke.

Trial Status {#s6-1}
------------

At the moment, we have concluded the basic science study that underpins this clinical trial.[@R26] The current phase of this project involves human resources and infrastructure aspects.

Safety Considerations {#s6-2}
---------------------

Treatment will be discussed daily between the staff of the critical care unit and the researchers who participate in the study, who will also be available in loco or by phone for additional clinical evaluation, if necessary. Families will receive daily reports on the clinical status of their relative who is enrolled in the study, and a contact number will be provided for further questions.

Follow-Up {#s6-3}
---------

Research participants will be followed in the hospital where they receive treatment via regular consultations at the neurosurgery outpatient units or via evaluation at the casualty department, if necessary.

Data Management and Statistical Analysis {#s6-4}
----------------------------------------

Data will be stored in 2 personal computers located in the institutions that participate in the study and will be accessible by the authors of this article or staff members who are formally authorized by one of the authors (M.J.T.).

The end point of this project is mortality within 180 days after SAH. Mortality, functional outcomes, and the presence of delayed ischemic neurological deficits will be correlated with the alterations in multimodal monitoring parameters and inflammatory and neuroregeneration markers.

Quality Assurance {#s6-5}
-----------------

The study follows the guidelines of Good Clinical Practices. The study coordinator will supervise data management, and files will be synchronized with a backup system. Adverse events will be communicated to the Agência Nacional de Vigilância Sanitária (Anvisa, National Agency of Sanitary Vigilance) and to the Research and Ethical Committees of both hospitals, who are also responsible for periodic analysis and revision of the study progress.

Expected Study Outcome {#s6-6}
----------------------

The expected study outcome is the identification of a correlation between mortality and functional outcomes and neuroregeneration markers. This finding would reveal potential biomarkers for monitoring poor-grade SAH cases and would raise the possibility that injury-induced neurogenesis plays a role in clinical recovery after severe brain injury.

Duration of the Project {#s6-7}
-----------------------

This project will take up to 36 months. The first 12 months were dedicated to performing the basic science research that underpins the clinical trial, setting up the infrastructure, and importing equipment and reagents. The remaining 24 months will be spent in the proper development of the clinical trial.

Project Management {#s6-8}
------------------

The project involves the collaboration of a multidisciplinary team under the supervision of Dr Teixeira.

Ethics {#s6-9}
------

This protocol has been approved by the Brazilian Clinical Trials Registry (Rebec), a primary registry that participates in the [WHO International Clinical Trials Registry Platform](http://www.who.int/ictrp/network/primary/en/index.html).
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